MedPath

Impact of Endothelial Cell Activation and Modifications of Haemostasis Induced by Infective Endocarditis on the Risk of Embolism

Not Applicable
Completed
Conditions
Infective Endocarditis
Registration Number
NCT00947817
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Brief Summary

Prospective study including all the consecutive patients admitted at the Department of Cardiology, Timone Hospital wih a definite diagnosis of IE according to the modified Duke criteria. The period of inclusion will be for 24 months. Eighty patients and age-matched control subject will be included. Primary end point are EE occurring during the antimicrobial treatment and secondary end points will be 6-month mortality, vegetation length and the impact of antimicrobial treatment on inflammation-induced procoagulant changes and endothelial cell activation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
77
Inclusion Criteria
  • All the patients presenting certain diagnosis of infectious endocardite according to the criteria of modified Duke
Exclusion Criteria
  • Age < 18 years
  • Pregnancy and feeding
  • Health not allowing to give the assent
  • Innate abnormalities of the haemostasis
  • More than a week before the inclu antibiothérapie adapted begun

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Embolic events occurring during the antimicrobial treatment a30 months
Secondary Outcome Measures
NameTimeMethod
Will be 6-month mortality, vegetation length and the impact of antimicrobial treatment on inflammation-induced procoagulant changes and endothelial cell activation.30months

Trial Locations

Locations (1)

Département de Cardiologie, Unité Valvulopathies et Insuffisance Cardiaque, Hôpital de la Timone,

🇫🇷

Marseille, Paca, France

Département de Cardiologie, Unité Valvulopathies et Insuffisance Cardiaque, Hôpital de la Timone,
🇫🇷Marseille, Paca, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.